It is an object of the present invention to provide a therapeutic agent for NK-cell tumor. According to the present invention, a therapeutic agent for NK-cell tumor, which comprises a substance that recognizes a transferrin receptor, is provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/02 - Antineoplastic agents specific for leukemia
2.
METHOD FOR IDENTIFYING COMMON L CHAIN FOR USE IN PRODUCTION OF MULTISPECIFIC ANTIBODY
The problem addressed by the present invention is to provide a method for identifying a common L chain for use in the production of a multispecific antibody. The present invention provides a method for identifying a common L chain for use in the production of a multispecific antibody, the method comprising: (1) a step for producing a first library containing a plurality of antibodies that recognize a first antigen; (2) a step for producing a second library containing a plurality of antibodies that recognize a second antigen; and (3) a step for selecting, from the first library and the second library, an antibody that recognizes the first antigen and an antibody that recognizes the second antigen that have a common L chain.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present invention addresses the problem of defining an appropriate dose regiment and an appropriate dosage for an anti-TfR antibody, which can suppress promotion of forming red blood cells without inducing a symptom of systemic anemia in a patient with polycythemia. According to the present invention, provided is a therapeutic agent for polycythemia, which includes an antibody recognizing amino acid residues lying between a 629th and a 633th in a human transferrin receptor. After a first administration of the antibody is performed at a dosage of 0.25-20 mg/kg, a second administration is not performed in at least four weeks or more.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention addresses the problem of providing radiolabeled anti-CDH3 antibodies that exhibit an excellent antitumor effect, and a cancer treatment agent containing the same. The present invention relates to anti-CDH3 antibodies labeled with 225Ac, and to a cancer treatment agent containing the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
It is an object of the present invention to provide an ROS production-enhancing agent. According to the present invention, an ROS production-enhancing agent, comprising a substance that recognizes a transferrin receptor, is provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
6.
METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY
National University Corporation Tokai National Higher Education and Research System (Japan)
PERSEUS PROTEOMICS INC. (Japan)
Inventor
Kiyoi, Hitoshi
Ishikawa, Yuichi
Nakashima, Marie
Ohira, Yuta
Oya, Junpei
Nomura, Fumiko
Katsumi, Keiko
Sakamoto, Aya
Ukai, Yoshinori
Matsuura, Tadashi
Abstract
It is an object of the present invention to provide a method for determining the medicinal effect or sensitivity of an anti-transferrin receptor antibody. According to the present invention, provided is a method for determining the medicinal effect or sensitivity of an anti-human transferrin receptor antibody having an action to inhibit the binding between human transferrin and a human transferrin receptor, wherein the method uses an intracellular iron content as an indicator.
G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
The present invention addresses the problem of providing a therapeutic agent for NK cell tumor. According to the present invention, a therapeutic agent for NK cell tumor is provided, which comprises a substance capable of recognizing a transferrin receptor.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
Inventor
Nomura, Fumiko
Matsuura, Tadashi
Zhang, Lilin
Aikawa, Yoichi
Asao, Takayuki
Yokobori, Takehiko
Abstract
It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
It is an object of the present invention to provide a therapeutic drug for polycythemia. According to the present invention, provided is a therapeutic drug for polycythemia, comprising an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
The present invention addresses the problem of providing an ROS production promoter. The present invention provides an ROS production promoter that contains an agent that recognizes a transferrin receptor.
It is an object of the present invention to provide an agent for inhibiting iron uptake into cells wherein the agent targets TfR, and an agent for inhibiting the binding between human Tf and human TfR. The present invention provides an agent for inhibiting iron uptake into cells which comprises an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 43/00 - Drugs for specific purposes, not provided for in groups
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
PERSEUS PROTEOMICS INC. (Japan)
Inventor
Kiyoi Hitoshi
Ishikawa Yuichi
Nakashima Marie
Ohira Yuta
Oya Junpei
Nomura Fumiko
Katsumi Keiko
Sakamoto Aya
Ukai Yoshinori
Matsuura Tadashi
Abstract
The present invention addresses the problem of providing a method for determining the sensitivity or medicinal effect of an anti-transferrin receptor antibody. The present invention provides a method that is for determining the sensitivity or medicinal effect of an anti-human transferrin receptor antibody having an effect of inhibiting binding between human transferrin and a human transferrin receptor, and that uses the amount of intracellular iron as an index.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
Inventor
Nomura Fumiko
Matsuura Tadashi
Zhang Lilin
Aikawa Yoichi
Asao Takayuki
Yokobori Takehiko
Abstract
The present invention addresses the problem of providing a therapeutic agent for carcinomatous peritonitis. The present invention provides a therapeutic agent that is for carcinomatous peritonitis and that contains an antibody that recognizes a transferrin receptor.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention addresses the problem of providing a therapeutic agent for polycythemia. According to the present invention, provided is a therapeutic agent for polycythemia, the inhibitor comprising antibodies that recognize the 629th to 633rd amino acids in human transferrin receptor.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention addresses the problem of providing an inhibitor of cellular iron uptake targeting TfR, and an inhibitor of binding between human Tf and human TfR. According to the present invention, provided is an inhibitor of cellular iron uptake, said inhibitor comprising an antibody which recognizes the 629th to 633rd amino acids in human transferrin receptor.
177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
18.
ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO CD147 MOLECULE, AND USE THEREOF
Provided are a monoclonal antibody capable of specifically binding to human CD147, and a use thereof for treatment against various types of cancer characterized by CD147 expression. The monoclonal antibody against human CD147 or a fragment containing an antigen-binding region thereof has properties a-c, namely, a. reacting against a cancer cell strain which expresses human CD147, b. reacting against a cell strain which expresses cynomolgus monkey CD147, and c. exhibiting in vivo anti-tumor activity against cancer cells which express human CD147.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
20.
Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof
The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human κ subgroup I consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the light chain variable region.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
21.
Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
22.
Antibody capable of specifically recognizing transferrin receptor
The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.
C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
The objective of the present invention is to provide a variety of anti-podoplanin antibodies that can be used as drugs and reagents. The present invention provides an anti-podoplanin antibody or an antigen binding fragment thereof having an epitope in any of the following regions in the podoplanin amino acid sequence represented by SEQ ID. No. 1: (i) 56th position - 80th position; (ii) 81st position - 103rd position; (iii) 81st position - 88th position; and (iv) 25th position - 57th position.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The purpose of the present invention is to provide an anti-ITGA6/B4 human antibody which is capable of inhibiting the adhesion of cancer cells in a bone marrow niche, and significantly increasing the strength of the effect of an anti-cancer drug against an anticancer-drug-resistant strain, by specifically recognizing the ITGA6B4 complex expressed on a cell membrane, and inhibiting the adhesion of the ITGA6B4 complex and laminin to one another. The present invention provides an antibody to integrin A6B4 which specifically recognizes the human integrin A6B4 complex and inhibits intercellular adhesion.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY (Japan)
PERSEUS PROTEOMICS INC. (Japan)
Inventor
Kurosawa Yoshikazu
Oshima Nobuko
Okuno Yoshinobu
Mitomo Katsuyuki
Kouda Katsushi
Abstract
The purpose of the present invention is to provide a novel antibody having high avidity and high neutralizing activity with respect to an influenza virus. The present invention provides an antibody for neutralizing the H1-type influenza virus and/or the H5-type influenza virus, which have: a heavy chain variable region having a CDR composed of a specific heavy chain first complementarity determining region (VH-CDR1), a heavy chain second complementarity determining region (VH-CDR2), and a heavy chain third complementarity determining region (VH-CDR3); and a light chain variable region having a CDR composed of a specific light chain second complementarity determining region (VL-CDR2), and a light chain third complementarity determining region (VL-CDR3).
Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
28.
ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND UTILIZATION OF SAME
The present invention addresses the problem of producing an anti-CDH3 humanized antibody having lower immunogenicity and provide an anti-CDH3 humanized antibody-drug conjugate using the same, said anti-CDH3 humanized antibody-drug conjugate being capable of more efficiently killing CDH3-expressing cancer cells. Provided is an anti-CDH3 humanized antibody-drug conjugate produced by linking an anti-CDH3 humanized antibody to a cytotoxic drug, wherein: the anti-CDH3 humanized antibody comprises complementarity determining region sequences originated from the heavy chain variable region of an antibody that is produced by a cell (Deposition No. NITE BP-1536) and complementarity determining region sequences originated from the light chain variable region thereof; the framework region sequences in the heavy chain variable region comprise a heavy chain human subgroup III consensus framework sequence or a human germ line sequence selected at the optimum alignment; and the framework region sequences in the light chain variable region include a light chain human κ subgroup I consensus framework sequence or a human germ line sequence selected at the optimum alignment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides an antibody wherein a first heavy chain complementarity determining region (VH CDR1), a second heavy chain complementarity determining region (VH CDR2), and a third heavy chain complementarity determining region (VH CDR3) are SEQ ID NOs: 1, 2 and 7, respectively, and a first light chain complementarity determining region (VL CDR1), a second light chain complementarity determining region (VL CDR2), and a third light chain complementarity determining region (VL CDR3) are SEQ ID NOs: 4, 5 and 6, respectively.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided is a monoclonal antibody exhibiting greater stimulatory activity than conventional anti CD40 monoclonal antibodies. This anti-human CD40 monoclonal antibody, or an antigen binding fragment thereof, which exhibits proliferation-inhibiting activity with respect to human CD40 antigen-expressing cells, in the absence of effector cells, specifically binds to: a) an epitope including amino acid residues 21-37 of a human CD40 amino acid sequence (SEQ ID NO: 1); or b) an epitope including amino acid residues 38-61 of the human CD40 amino acid sequence (SEQ ID NO: 1).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided is a monoclonal antibody which exhibits even greater ADCC activity, without the stimulatory activity exhibited by conventional anti CD40 monoclonal antibodies. This anti-human CD40 monoclonal antibody, or an antigen-binding fragment thereof, specifically binds to an epitope including amino acid residues 62-77 or 105-145 of a human CD40 amino acid sequence (SEQ ID NO: 1), without exhibiting proliferation-inhibiting activity in the absence of effector cells with respect to human CD40 antigen-expressing cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
33.
AGENT FOR TREATING OR PREVENTING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
The present invention provides an agent for treating or preventing systemic inflammatory response syndrome (SIRS) containing: a polypeptide comprising the same or substantially the same amino acid sequence as the N-terminus domain of pentraxin 3, able to bind to histones to form a polypeptide aggregate; or a pharmacologically acceptable salt thereof. The present invention also provides a quantifying method and reagent for quantifying histones using said polypeptide or pharmacologically acceptable salt thereof. The present invention furthermore provides a polypeptide aggregate comprising said polypeptide or pharmacologically acceptable salt thereof and histones, and a method for producing the same.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 39/00 - Medicinal preparations containing antigens or antibodies
35.
CONJUGATE OF ANTI-CDH3 (P-CADHERIN) ANTIBODY AND DRUG
The purpose of the present invention is to provide an (anti-CDH3 antibody)-drug conjugate which can highly efficiently kill a cancer cell capable of expressing CDH3. The present invention provides an immunological complex produced by linking an antibody against CDH3 or a fragment thereof that is capable of binding to CDH3 to a chemotherapeutic agent.
NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES (Japan)
PERSEUS PROTEOMICS INC. (Japan)
Inventor
Kurosawa Yoshikazu
Saga Tsuneo
Tsuji Atsushi
Sudo Yukio
Abstract
The present invention relates to a high-precision image-based tumor diagnosis agent which contains an antibody capable of specifically recognizing a transferrin receptor (TfR) on a cell membrane. Provided is the image-based tumor diagnosis agent which contains the antibody in which an antibody that recognizes a human transferring receptor is marked by a radionuclide.
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The problem addressed is to provide an anti-CDH3 antibody having cytotoxic activity on cells that express CDH3, wherein the recombinant antibody is expected to have fewer side effects than antibodies derived from animals other than humans and the therapeutic effect is expected to be long-lasting. The present invention provides a recombinant antibody having cytotoxic activity on cells that express CDH3 that reacts specifically with an epitope present at positions 108-131 or 551-654 of an amino acid sequence shown by SEQ ID NO:38, which is the extracellular region of human CDH3.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The purpose of the present invention is to provide a complete human anti-human TfR antibody that specifically recognises human TfR, inhibits the survival and multiplication of cancer cells in which TfR is overexpressed, and exhibits no immunogenicity in humans. The antibody that specifically responds to human TfR respectively contains as the heavy chain first complementarity determining region (VHCDR1), the heavy chain second complementarity determining region (VHCDR2), and the heavy chain third complementarity determining region (VHCDR3), amino acid sequences represented by any of the following SEQ ID NOs.: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, 115-117.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention addresses the problem of providing a high-affinity anti-cadherin antibody. The present invention provides an anti-cadherin antibody which recognizes the cadherin domain 1 (EC1) or cadherin domain 2 (EC2) of cadherin and has a Kd value, which is the antibody concentration that imparts 50% binding with antigen, of 10 nM or less.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The purpose to be achieved by the present invention is to provide: an anti-cadherin antibody having high internalizing capability; and an (anti-cadherin antibody)-(medicinal agent) conjugate which can efficiently kill cancer cells that express cadherin and which is produced using the anti-cadherin antibody. The present invention provides an anti-cadherin antibody which can recognize a cadherin domain 1 (EC1) in cadherin and has high internalizing capability.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
[Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor.
[Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/24 - Human cells one of the fusion partners being a B lymphocyte
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed are: a radioactive metal-labeled anti-cadherin antibody which specifically and highly accumulates in cancer tissues; a highly safe drug for the treatment of cancer, which has a high antitumor effect; and a diagnostic for cancer. Specifically disclosed is a radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metal element to an anti-cadherin antibody via a metal chelate reagent.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
Provided is an anti-cadherin antibody having strong antibody-dependent cytotoxicity. The anti-cadherin antibody recognizes cadherin domain 4 (EC4), cadherin domain (EC5), or a domain upstream from EC1, and has an antibody-dependent cytotoxicity of 30% or greater at an antibody concentration of 1 µg/mL.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed is a streptavidin mutant in which the immunogenicity (antigenicity) of streptavidin in mammals has been reduced. The core streptavidin amino acid sequence of the streptavidin mutant, described by sequence no. 2, contains an amino acid sequence in which (a) the arginine at amino acid residue 72 is replaced with another amino acid, and (b) any one or more of the tyrosine at amino acid residue 10, tyrosine at amino acid residue 71, glutamic acid at amino acid residue 89, arginine at amino acid residue 91, and glutamic acid at amino acid residue 104 is replaced with another amino acid, thereby reducing the immunogenicity compared to wild-type streptavidin.
Disclosed is a monoclonal antibody against human GPR87. Also disclosed is a novel means for diagnosing or treating a malignant tumor. The monoclonal antibody against human GPR87 can recognize human GPR87 expressed on a cell membrane in such a state that the three-dimensional structure thereof is retained, wherein the epitope is located on the extracellular domain of full length human GPR87. The antibody can also recognize GPR87 that is expressed in a cell endogenously. Therefore, the antibody is useful for a biochemical analysis or the like of GPR87, and is also useful for an immunohistological diagnosis of squamous cell carcinoma or the like. The antibody is potentially useful as an antibody for use in the PET diagnosis or treatment of squamous cell carcinoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention is directed to diagnostic methods relating to metabolic syndrome that are based upon the concentration of pentraxin-3 in the blood, plasma or serum of a patient.
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japan)
PERSEUS PROTEOMICS INC. (Japan)
Inventor
Nakajima, Atsushi
Yoneda, Masato
Fujita, Koji
Hamakubo, Takao
Aburatani, Hiroyuki
Kodama, Tatsuhiko
Sagara, Mina
Abstract
Disclosed are: a method for determining the occurrence of progressive non-alcoholic steatohepatitis; and a method for determining the occurrence of hepatic fibrosis in non-alcoholic fatty liver disease. Specifically disclosed are: a method for determining the occurrence of progressive non-alcoholic steatohepatitis, which is characterized by measuring the PTX3 level in a sample collected from a patient suffering from non-alcoholic fatty liver disease; and a method for determining the occurrence of hepatic fibrosis, which is characterized by measuring the PTX3 level in a sample.
Disclosed is a novel method for treating colorectal cancer. Specifically disclosed is a therapeutic agent for colorectal cancer, which comprises siRNA for AMIGO2 gene or an anti-AMIGO2 antibody or a fragment of the antibody.
Disclosed are: a novel method for diagnosing or treating lung cancer, prostate cancer, breast cancer, ovarian cancer or melanoma; and a diagnostic or therapeutic agent for cancer, which comprises an anti-AMIGO2 antibody.
Disclosed is a novel method for diagnosing and treating cancer. Specifically disclosed is a diagnostic agent or a therapeutic agent for cancer, which comprises an anti-HNT antibody.
Disclosed is a method for the diagnosis on the presence of inflammatory bowel disease and/or the activity of inflammatory bowel disease. Specifically disclosed is a method for the determination of the presence of inflammatory bowel disease and/or the activity of inflammatory bowel disease, which is characterized by measuring the level of PTX3 in a sample.
Disclosed is a method for the diagnosis of heart failure at an early stage. Specifically, disclosed is a method for the determination of the degree and/or prognosis of heart failure, characterized by measuring a PTX3 level in a sample by using an anti-PTX3 monoclonal antibody.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed is a novel diagnosis or therapeutic method for pancreatic cancer using a blood marker. Specifically, disclosed is a diagnostic or therapeutic agent for pancreatic cancer, which comprises an anti-AMIGO2 antibody.
A method of judging vascular disorders as a risk factor of myocardial infarction, angiopathic dementia, etc. at an early date, namely, mild vascular disorders. There is provided a method of judging the degree of mild vascular disorders, characterized in that the level of PTX3 in a test sample is measured with the use of anti-PTX3 monoclonal antibody.
It is intended to provide a method that enables an efficient and accurate proteomics analysis of a nuclear receptor protein complex even in the case of using a small amount of a sample containing the nuclear receptor protein. The method for the proteomics analysis of a nuclear receptor protein complex is characterized by subjecting a sample containing a nuclear receptor protein to an immunoprecipitation reaction using a support having a monoclonal antibody with specificity and high affinity for one type of nuclear receptor protein bound thereto and analyzing a protein complex separated by the immunoprecipitation reaction.
patents
